Inotek Pharmaceuticals Corporation Presents Positive Phase 2 Data of Trabodenoson in Glaucoma
11/8/2012 10:06:05 AM
More...
|
Inotek Pharmaceuticals Corporation to Present Phase 2 Data of Trabodenoson in Glaucoma at the Ophthalmology Innovation Summit
11/2/2012 8:34:08 AM
More...
|
Inotek Pharmaceuticals Corporation to Expand Phase 2 Clinical Trial in Glaucoma Based on Promising Preliminary Results
7/21/2011 10:25:48 AM
More...
|
Inotek Pharmaceuticals Corporation Initiates Multiple-Dose Phase 2 Clinical Trial of INO-8875 in Patients With Glaucoma
6/17/2010 9:40:28 AM
More...
|
Inotek Pharmaceuticals Corporation Brings In $18M For Eye Treatments
6/11/2010 8:30:19 AM
More...
|
Inotek Pharmaceuticals Corporation Presents Preclinical Data at ARVO Confirming That INO-8875 Lowers IOP by Increasing Outflow Through the Trabecular Meshwork
5/4/2010 11:54:54 AM
More...
|
Inotek Pharmaceuticals Corporation to Present New Preclinical Data on Novel Mechanism of Action for Lead Glaucoma Candidate INO-8875
4/27/2010 10:55:36 AM
More...
|
Inotek Pharmaceuticals Corporation to Present at the Cowen and Company 30th Annual Health Care Conference on Thursday, March 11
3/4/2010 10:51:37 AM
More...
|
Inotek Pharmaceuticals Corporation's Novel Glaucoma Candidate, INO-8875, Significantly Reduces Intraocular Pressure in Phase 1/2 Study
6/25/2009 8:51:05 AM
More...
|
Inotek Pharmaceuticals Corporation Presents Preclinical Data in Support of Novel Glaucoma Candidate, INO-8875 at Association for Research in Vision & Ophthalmology
5/6/2009 9:11:12 AM
More...
|
|